HS
BPMC

HighVista Strategies’s Blueprint Medicines BPMC Stock Holding History

HighVista Strategies’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,108
Closed -$612K – 116
2022
Q2 		$612K Buy
+12,108
New +$709K 0.37% 67
2022
Q1 		– Sell
-13,843
Closed -$1.48M – 88
2021
Q4 		$1.48M Buy
13,843
+1,127
+9% +$118K 1.18% 23
2021
Q3 		$1.31M Buy
12,716
+3,911
+44% +$364K 0.86% 29
2021
Q2 		$774K Buy
+8,805
New +$807K 0.55% 58
2020
Q3 		– Sell
-5,396
Closed -$421K – 120
2020
Q2 		$421K Buy
+5,396
New +$365K 0.35% 50

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HighVista Strategies's BPMC Position: Q3 2022 in Review

HighVista Strategies sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 12,108 shares — an estimated $612K sold.

HighVista Strategies first reported a position in BPMC in Q2 2020 and held it in 5 quarters. The position peaked at $1.48M in Q4 2021. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

  • HighVista Strategies reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
  • HighVista Strategies sold 12,108 Blueprint Medicines shares in Q3 2022, an estimated $612K.
  • HighVista Strategies first reported a position in Blueprint Medicines in Q2 2020 and held it in 5 quarters.
  • HighVista Strategies's Blueprint Medicines position peaked at $1.48M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.